MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12967-026-08669-y

Медицинская библиотека · Journal of translational medicine · 2026

AI-Driven discovery and experimental validation of covalent FGFR4 inhibitors for hepatocellular carcinoma.

Gao Mingjie, Zhao Weiyi, Zhang Pengfei, Pei Mengmeng, Zhang Zhenyu, Chen Min, Han Bin, Chen Xuemei, Ni Biao, Yang Jiawei, Wang Zengwu, Du Xiaolong, Wang Shaoqiang

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

FGFR4 signaling is an essential driver in hepatocellular carcinoma. However, traditional screening is often time-consuming, highlighting a need for efficient strategies to identify covalent chemotypes and accelerate FGFR4 drug discovery.

METHODS

We established an integrated AI-driven virtual screening framework to discover FGFR4 covalent inhibitors. The theoretical predictions were evaluated through a biochemical pipeline, encompassing in vitro FGFR4 kinase assays, immunoblotting of intracellular signaling cascades, and bottom-up LC-MS/MS peptide mapping.

RESULTS

Biological validation of the computational predictions identified five distinct chemical scaffolds (hits 1, 2, 5, 7, and 8) exhibiting antiproliferative activity. The two most active candidates, hit 1 and hit 2, were selected for further mechanistic profiling. These compounds demonstrated dose-dependent FGFR4 kinase inhibition with IC50 values of 1.06 μM and 3.57 μM, respectively. Cellular assays revealed that both compounds attenuate FGFR4 autophosphorylation and its downstream FRS2/ERK1/2 signaling cascade without inducing non-specific protein degradation. Furthermore, bottom-up LC-MS/MS peptide mapping provided direct structural evidence that hit 1 and hit 2 engage the target cysteine residue via a Michael addition mechanism.

CONCLUSIONS

Our AI-guided computational workflow identified multiple covalent FGFR4 inhibitors with measurable biological activity. Hit 1 and hit 2 represent structurally characterized covalent scaffolds. This study provides chemical starting points for targeted HCC therapy and demonstrates the integration of theoretical prediction and experimental validation in covalent drug discovery.

Для цитирования: Gao Mingjie, Zhao Weiyi, Zhang Pengfei, Pei Mengmeng, Zhang Zhenyu, Chen Min, Han Bin, Chen Xuemei, Ni Biao, Yang Jiawei, Wang Zengwu, Du Xiaolong, Wang Shaoqiang. AI-Driven discovery and experimental validation of covalent FGFR4 inhibitors for hepatocellular carcinoma.. Journal of translational medicine. 2026. DOI: 10.1186/s12967-026-08669-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.